OTCMKTS:RLMD

Relmada Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy RLMD

*Your capital is at risk

$6.33

-0.0900 (-1.40%)

At Close: Jun 03, 2026

Relmada Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 13.96M and sold 702.47K RLMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	13.96M shares
● Sell	702.47K shares
84% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Nov 05, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Kelly Paul Edward Chief Operating Officer	C-Suite Officer	400 000 Value: $268.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Kelly Paul Edward Chief Operating Officer	C-Suite Officer	400 000 Value: $268.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Fedeli Fabiana Director	Director	100 000 Value: $67.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Glasspool John Director	Director	100 000 Value: $67.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Casamento Charles J Director	Director	100 000 Value: $67.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Traversa Sergio Chief Executive Officer	CEO / President	800 000 Value: $536.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Shenouda Maged Chief Financial Officer	C-Suite Officer	600 000 Value: $402.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Ence Chuck Ca And Co	Officer	400 000 Value: $268.0K
May 20, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	60 000 Value: $31.4K
May 20, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	147 686 Value: $82.2K
May 20, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	147 686 Value: $82.2K
May 20, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	60 000 Value: $31.4K
May 19, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	90 000 Value: $43.7K
May 19, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	30 000 Value: $15.0K
May 19, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	30 000 Value: $15.0K
May 19, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	90 000 Value: $43.7K
May 16, 2025 Buy	Common Stock P-Purchase	Kelly Paul Edward Chief Operating Officer	C-Suite Officer	200 000 Value: $86.1K
May 16, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	50 000 Value: $22.1K
May 16, 2025 Buy	Common Stock P-Purchase	Ence Chuck Ca And Co	Officer	228 961 Value: $103.3K
May 16, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	172 314 Value: $77.5K
May 16, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	172 314 Value: $77.5K
May 16, 2025 Buy	Common Stock P-Purchase	Ence Chuck Ca And Co	Officer	228 961 Value: $103.3K
May 16, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	50 000 Value: $22.1K
May 16, 2025 Buy	Common Stock P-Purchase	Kelly Paul Edward Chief Operating Officer	C-Suite Officer	200 000 Value: $86.1K
Oct 22, 2024 Sell	Common Stock G-Gift	Casamento Charles J Director	Director	13 000 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RELMADA THERAPEUTICS, INC.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ...

Read Full Profile Here